iStar Inc. (NYSE:STAR) shares moved down -2.59% in last trading session and ended the day at $9.40. STAR Gross Margin is 61.20% and its has a return on assets of -1.70%. iStar Inc. (NYSE:STAR) quarterly performance is -28.57%.
On 10 January, iStar Inc. (NYSE:STAR) which has introduced a unique lakefront lifestyle at Naples Reserve, was named Developer of the Year by Builder and Developer magazine.
Intel Corporation (NASDAQ:INTC) shares decreased -0.70% in last trading session and ended the day at $29.59. INTC Gross Margin is 62.90% and its has a return on assets of 12.40%. Intel Corporation (NASDAQ:INTC) quarterly performance is -11.29%.
Intel Corporation (NASDAQ:INTC) publicly declared its love for drones, revealing possible plans to power this future technology with its line of premium chips. At the Consumer Electronics Show 2016, the semiconductor giant, known for making PC processors, showcased an unmanned aircraft built in partnership with the Chinese aerial technology firm, Yuneec, called the Typhoon H.
On 20 January, Nektar Therapeutics (NASDAQ:NKTR) shares advanced 3.85% and was closed at $14.57. NKTR EPS growth in last 5 year was 17.70%. Nektar Therapeutics (NASDAQ:NKTR) year to date (YTD) performance is -13.53%.
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $16.00) after providing an outlook for 2016, which they like.
Spark Networks, Inc. (NYSEMKT:LOV) shares advanced 1.55% in last trading session and ended the day at $3.28. LOV Gross Margin is 51.50% and its has a return on assets of 11.30%. Spark Networks, Inc. (NYSEMKT:LOV) quarterly performance is -2.96%.
Spark Networks, Inc. (NYSEMKT:LOV) announced subscriber metrics as of the end of the fourth quarter 2015. ‘Paying Subscribers’ are defined as individuals who have paid a monthly fee for access to communication and Web site features beyond those provided to our members.
Can-Fite BioPharma Ltd. (NYSEMKT:CANF) caters to the Healthcare space. Its weekly performance is -16.67%. On the last day of trading company shares ended up at $2.00. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) distance from 50-day simple moving average (SMA50) is -31.94%.
Can-Fite BioPharma Ltd. (NYSEMKT:CANF) announced the United States Patent and Trademark Office has issued a Notice of Allowance for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. This composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator including the preparation of its pharmaceutical compositions and its use in patients across all therapeutic indications. Can-Fite is currently developing this invention for the treatment of sexual dysfunction with its next-generation drug, CF602.